AbbVie (NYSE:ABBV) Shares Down 2.2% on Analyst Downgrade

AbbVie Inc. (NYSE:ABBV) shares traded down 2.2% during mid-day trading on Wednesday after Citigroup lowered their price target on the stock from $235.00 to $230.00. Citigroup currently has a neutral rating on the stock. AbbVie traded as low as $216.70 and last traded at $218.9880. 4,986,646 shares were traded during mid-day trading, a decline of 31% from the average session volume of 7,220,492 shares. The stock had previously closed at $223.93.

A number of other analysts have also weighed in on the company. DZ Bank lowered AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price for the company. in a research note on Tuesday, November 4th. Piper Sandler restated an “overweight” rating and issued a $289.00 price objective (up previously from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. Scotiabank began coverage on shares of AbbVie in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 target price for the company. Erste Group Bank cut shares of AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. Finally, Guggenheim raised their price target on shares of AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a report on Monday, October 20th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $249.37.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Investor enthusiasm around a reported bispecific trial win and management’s renewed R&D pledge — this strengthens AbbVie’s pipeline narrative and long-term growth prospects. Does AbbVie’s Bispecific Trial Win and R&D Pledge Change The Bull Case For AbbVie (ABBV)?
• Positive Sentiment: Retrospective coverage highlighting AbbVie’s strong 2025 performance reinforces confidence in management’s handling of patent cliffs and portfolio transitions. Why AbbVie Stock Trounced the Market in 2025
• Positive Sentiment: Allergan Aesthetics unveiled new clinical and portfolio data that support continued strength in the aesthetics business — a valuable, higher-margin growth pillar for AbbVie. Allergan Aesthetics Unveils New Data Across Facial Injectables
• Positive Sentiment: On-air analyst commentary recommended staying long ABBV, adding short-term buying pressure from retail and institutional viewers. AbbVie, SLB, Amphenol, And More On CNBC’s ‘Final Trades’
• Neutral Sentiment: Coverage of AbbVie’s drug affordability deal notes management is trying to balance price/access commitments with continued R&D and patient-growth plans — reduces regulatory risk but may cap pricing upside. AbbVie Balances Drug Affordability Deal With R&D And Patient Growth Plans
• Neutral Sentiment: Investor note questioning whether recent gains leave ABBV fairly priced based on DCF and price-to-sales signals — flags valuation scrutiny even as shares rally. Is AbbVie (ABBV) Pricing Reflect Its DCF And Price To Sales Signals After Recent Gains
• Neutral Sentiment: AbbVie launched a migraine-focused awareness program (“Love in Mind”) — positive for brand, patient engagement and uptake of migraine therapies but largely a longer-term marketing play. AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine
• Negative Sentiment: Near-term earnings preview from Zacks suggests AbbVie may lack the setup for an earnings beat next week, which could increase volatility if guidance or execution disappoints. AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ABBV. Evolution Wealth Management Inc. bought a new position in AbbVie during the second quarter worth about $26,000. Chelsea Counsel Co. acquired a new stake in shares of AbbVie in the 3rd quarter valued at approximately $26,000. Spurstone Advisory Services LLC bought a new position in AbbVie during the 2nd quarter worth approximately $28,000. Westend Capital Management LLC acquired a new position in AbbVie during the fourth quarter valued at approximately $29,000. Finally, Texas Capital Bancshares Inc TX acquired a new stake in AbbVie in the third quarter worth $31,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Price Performance

The company has a market capitalization of $389.56 billion, a P/E ratio of 166.98, a PEG ratio of 0.90 and a beta of 0.36. The business’s 50-day moving average price is $224.67 and its two-hundred day moving average price is $218.02.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.00 EPS. Research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.